Medicine
Wynzora 64 mg/50 mcg per g cream
Wynzora 64 mg/50 mcg per g cream is a prescription medicine containing Betamethasone dipropionate and Calcipotriene for topical use, marketed by MC2 Therapeutics, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Do not freeze. Store between 20°C-25°C (68°F-77°F), excursions permitted…
Key facts
- Active ingredient (INN)
- Betamethasone dipropionate and Calcipotriene
- Brand
- Wynzora
- Strength
- 64 mg/50 mcg per g
- Dosage form
- Cream
- Route
- Topical
- Packs
- 1 tube
- Marketing authorisation holder
- MC2 Therapeutics
- Manufacturer
- MC2 Therapeutics
- Origin register
- US FDA, United States
- Storage
- Do not freeze. Store between 20°C-25°C (68°F-77°F), excursions permitted between 15°C-30°C (59°F-86°F). Protect from light and excessive heat.
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- HS code (indicative)
- 3004.32Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 30 June 2021
- Identifiers
- RxCUI 2471873, 2471878DailyMed set ID 36c5c818-0d40-445e-a3c0-0f46723a25e2NDC 73499-001Application NDA213422
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 1 tube in 1 carton / 60 g in 1 tube | 73499-001-01 | MC2 Therapeutics | 30 June 2021 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 9 January 2006 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Other strengths and forms of Betamethasone dipropionate and Calcipotriene
Clinical summary
Betamethasone dipropionate and Calcipotriene is a fixed-dose combination of a corticosteroid and a vitamin D analog indicated for the topical treatment of plaque psoriasis in patients 12 years of age and older. MedsAcross supplies Betamethasone dipropionate and Calcipotriene for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about Betamethasone dipropionate and CalcipotrieneFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Calcipotriene and Betamethasone Dipropionate prescribing information (Prasco Laboratories) · U.S. National Library of Medicine, DailyMed
Need Wynzora 64 mg/50 mcg per g cream for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.